Polymer therapeutics - Polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities

Journal of Drug Targeting

Volumn 14, Issue 6, 2006, Pages 337-341

  Duncan, Ruth ^a   Ringsdorf, Helmut ^b   Satchi Fainaro, Ronit ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ALANINE; ALLYLAMINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ASPARAGINASE MACROGOL; DENDRIMER; DEXTRIN 2 SULFATE; DOXORUBICIN; GLUTAMIC ACID; HERBACEOUS AGENT; IODINATED POPPYSEED OIL; LIPOSOME; LYSINE; MACROGOL; MESCALINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PLASMA SUBSTITUTE; POLYALLYLAMINE; POLYGLUTAMIC ACID; POLYLYSINE; POLYMER; POLYPEPTIDE; POLYSACCHARIDE; POVIDONE; PROTEIN DERIVATIVE; PYRAN COPOLYMER; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; GENE DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOTOXICITY; LIVER CANCER; MACROMOLECULE; MICELLE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; PHARMACOGNOSY; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM;

CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; POLYMERS; TRANSFECTION;

EID: 33746985456     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600833856     Document Type: Article

References (28)

1. Bader, H and Dorn, K and Hupfer, B and Ringsdorf, H. (1985) Polymeric monolayers and liposomes as models for biomembranes. How to bridge the gap between polymer science and membrane biology? Adv Polymer Sci, 64, pp. 1-62.
2. Breslow, DS. (1976) Biologically active synthetic polymers Pure Appl Chem, 46, pp. 103-113. Seymour LW (1991) Synthetic polymers with intrinsic anticancer activity. J Bioact Comp Polymers 6:178-216
3. Davis, FF. (2002) The origin of pegnology Adv Drug Del Rev, 54, pp. 457-458.
4. de Duve, C and de Barsy, T and Poole, B and Trouet, A and Tulkens, P and van-Hoof, F. (1974) Lysosomotropic agents Biochem Pharmacol, 23, pp. 2495-2531.
5. Dhal, PK and Holmes-Farley, SR and Mandeville, WH and Neenan, TX. (2002) Polymeric Drugs Encyl Polym Sci Technol, 3rd Edn., pp. 555-580. Wiley-VCH
6. Duncan, R. (2003) The Dawning Era of polymer therapeutics Nat Rev Drug Discov, 2, pp. 347-360.
7. Duncan, R. (2003) Polymer-drug conjugates. In Handbook of anticancer drug development. (pp. 239-260). USA: Lippincott, Williams & Wilkins, Philadelphia.
8. Duncan, R. (2003) Polymer-drug conjugates. In Handbook of anticancer drug development. (pp. 239-260). Philadelphia: Lippincott Williams & Wilkins.
9. Duncan, R. (2005) N-(2-Hydroxypropyl)methacrylamide copolymer conjugates. In Polymeric drug delivery systems. (pp. 1-92). New York: Marcel Dekker, Inc.
10. Duncan, R and Izzo, L. (2005) Dendrimer biocompatibility and toxicity Adv Drug Del Rev, 57, pp. 2215-2237.
11. Duncan, R and Kopecek, J. (1984) Soluble synthetic polymers as potential drug carriers Adv Polymer Sci, 57, pp. 51-101.
12. Editorial. Nanomedicine: Grounds for optimism. The Lancet, 362; 673, (2003) NIH Roadmap for Nanomedicines, May 2004; Willis, R.C. (2004) Good things in small packages. Nanotech advances are producing mega-results in drug delivery. Modern Drug Discov. 30-36. European Science Foundation Policy Briefing (2005) ESF Scientific Forward Look on Nanomedicine 23 February 2005 (www.esf.org).
13. Ferrari, M. (2005) Cancer nanotechnology: Opportunities and challenges Nat Rev Cancer, 5, pp. 161-171.
14. Gebelein, CG and Carraher, CE. (1985) Bioactive polymeric systems. New York: Plenum Press.
15. Gros, L and Ringsdorf, H and Schupp, H. (1981) Polymeric antitumour agents on a molecular and cellular level Angew Chemie Int Ed Eng, 20, pp. 301-323.
16. Harris, JM and Chess, RB. (2003) Effect of pegylation on pharmaceuticals Nat Rev Drug Discov, 2, pp. 214-221.
17. Jatzkewitz, H. (1955) Peptamin (glycyl-l-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline) Z Naturforsch, 10 b, pp. 27-31.
18. Kakizawa, Y and Kataoka, K. (2002) Block copolymer micelles for delivery of gene and related compounds Adv Drug Deliv Rev, 54, pp. 203.
19. Lehn, JM. (1995) Supramolecular chemistry: Concepts and perspectives. New York: VCH.
20. Morawetz, H. (1985) Polymers: The origins and the growth of a science. New York: Wiley Interscience.
21. Pack, DW and Hoffman, AS and Pun, S and Stayton, PS. (2005) Design and development of polymers for gene delivery Nature Rev Drug Discov, 4, pp. 581-593.
22. Regelson, W. (1986) Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy J Bioact Compat Polymers, 1, pp. 84-106.
23. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers J Polym Sci Polymer Symp, 51, pp. 135-153.
24. Ringsdorf, H. (2004) Hermann staudinger and the future of polymer research: Jubilees - Beloved occasions for cultural piety Angew Chem Int Ed, 43, pp. 1064-1076.
25. Satchi-Fainaro, R and (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 Nature Med, 10, pp. 255-261.
26. Torchilin, VP. (2005) Recent advances with liposomes as pharmaceutical carriers Nature Rev Drug Discov, 4, pp. 145-160.
27. Wagner, E. (2004) Strategies to improve DNA polyplexes for in vivo gene transfer: Will "artificial viruses" be the answer? Pharm Res, 21, pp. 8-14.
28. Watson, JD and Crick, FH. (1953) Nature, 171, pp. 737-964.